Table 1.
Baseline patients’ sample description.
| Ticagrelor users | Clopidogrel users | |||||
|---|---|---|---|---|---|---|
| Diabetes | No diabetes | p | Diabetes | No diabetes | p | |
| 53 (100) | 244 (100) | 89 (100) | 281 (100) | |||
| Gender n (%) | ||||||
| Males | 42 (79.2) | 179 (73.4) | 0.487 | 54 (60.7) | 202 (71.9) | 0.049 |
| Females | 11 (20.8) | 65 (26.6) | 35 (39.3) | 79 (28.1) | ||
| Age in years median (min-max) | 64 (38-82) | 64 (29-90) | 0.744 | 69 (40-86) | 68 (39-89) | 0.059 |
| Males | 63 (38-81) | 62 (29-90) | 0.167 | 66 (40-84) | 63 (39-89) | 0.26 |
| Females | 69 (43-82) | 71 (43-88) | 0.218 | 74 (60-86) | 72 (56-88) | 0.513 |
| Patient weight in kg median (min-max) | 95 (60-121) | 84 (48-164) | <0.001 | 92 (47-158) | 82 (45-132) | <0.001 |
| Body weight index median (min-max) | 31 (23-43) | 28 (17-44) | <0.001 | 32 (16-50) | 28 (17-55) | <0.001 |
| Waist circumference median (min-max) | 99 (81-130) | 94 (63-122) | 0.001 | 104 (68-137) | 93 (69-128) | <0.001 |
| ST-elevation MI n (%) | ||||||
| STEMI | 16 (30.2) | 119 (48.8) | 0.015 | 28 (31.5) | 88 (31.3) | 1 |
| NSTEMI | 37 (69.8) | 125 (51.2) | 61 (68.5) | 193 (68.7) | ||
| MI in anamnesis n (%) | ||||||
| First | 33 (62.3) | 168 (68.9) | 0.418 | 56 (62.9) | 212 (75.4) | 0.029 |
| Recurrent | 20 (37.7) | 76 (31.1) | 33 (37.1) | 69 (24.6) | ||
| Smoking n (%) | ||||||
| Smokers | 9 (17) | 75 (30.1) | 0.045 | 17 (19.1) | 87 (31) | 0.031 |
| Non-smokers | 44 (83) | 169 (69.9) | 72 (80.9) | 194 (69) | ||
| Concomitant drug users | ||||||
| Diaprel n (%) | 8 (15.1) | — | — | 22 (24.7) | — | — |
| Glimepiride n (%) | 3 (5.7) | — | — | 2 (2.2) | — | — |
| Insulin n (%) | 19 (35.8) | — | — | 34 (38.2) | — | — |
| Metformin n (%) | 33 (62.3) | — | — | 60 (67.4) | — | — |
| ACE inhibitors n (%) | 47 (88.7) | 232 (95.1) | 0.105 | 79 (88.8) | 250 (88.9) | 1 |
| Angiotensin II | ||||||
| receptor antagonists n (%) | 5 (9.4) | 11 (4.5) | 0.175 | 12 (13.5) | 28 (10) | 0.335 |
| Beta | ||||||
| adrenoblockers n (%) | 50 (94.3) | 229 (93.9) | 1 | 86 (96.6) | 262 (93.2) | 0.309 |
| Statins n (%) | 53 (100) | 242 (99.2) | 1 | 84 (94.4) | 274 (97.5) | 0.17 |
| Spironolactone n (%) | 12 (22.6) | 60 (24.6) | 0.86 | 23 (25.8) | 62 (22.1) | 0.472 |
| Amiodarone n (%) | 3 (5.7) | 5 (2) | 0.155 | 1 (1.1) | 6 (2.1) | 1 |
| Ivabradin n (%) | 7 (13.2) | 24 (9.8) | 0.46 | 20 (22.5) | 42 (14.9) | 0.105 |
| Calcium Channel | ||||||
| Blockers n (%) | 8 (15.1) | 11 (4.5) | 0.009 | 11 (12.4) | 21 (7.5) | 0.192 |
| Diuretics n (%) | 20 (37.7) | 50 (20.5) | 0.012 | 41 (46.1) | 71 (25.3) | <0.0001 |
| Ranitidine n (%) | 35 (66) | 185 (75.8) | 0.166 | 59 (66.3) | 197 (70.1) | 0.52 |
| Proton pump inhibitors n (%) | 7 (13.2) | 18 (7.4) | 0.175 | 2 (2.2) | 5 (1.8) | 0.675 |
| Blood test parameters | ||||||
| Platelet count (x109/l) | 210 (109-491) | 228 (103-1000) | 0.09 | 213 (94-422) | 211 (101-796) | 0.692 |
| WBC (x109/l) | 9 (4-43) | 9 (3-22) | 0.788 | 9 (4-21) | 8 (4-28) | 0.206 |
| C-reactive protein (mg/l) | 9 (1-276) | 4 (1-379) | 0.115 | 5 (1-222) | 4 (1-255) | 0.064 |
| Creatinine (µmol/l) | 94 (53-262) | 89 (53-303) | 0.154 | 92 (47-478) | 87 (48-220) | 0.016 |
| Hemoglobin (g/l) | 132 (98-176) | 136 (89-172) | 0.437 | 137 (81-163) | 139 (50-170) | 0.143 |
WBC – white blood cells.